Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) – Equities research analysts at Zacks Investment Research cut their Q2 2022 earnings estimates for Opiant Pharmaceuticals in a note issued to investors on Thursday, May 12th. Zacks Investment Research analyst D. Bautz now anticipates that the technology company will post earnings per share of ($1.48) for the quarter, down from their previous forecast of ($1.45). Zacks Investment Research also issued estimates for Opiant Pharmaceuticals’ Q3 2022 earnings at ($1.55) EPS, Q4 2022 earnings at ($1.73) EPS and FY2022 earnings at ($7.18) EPS.
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($1.68). The firm had revenue of $4.47 million during the quarter, compared to analyst estimates of $7.13 million. Opiant Pharmaceuticals had a negative net margin of 13.70% and a negative return on equity of 15.28%. During the same period in the prior year, the firm posted ($0.66) earnings per share.
Several other brokerages have also commented on OPNT. TheStreet lowered shares of Opiant Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Monday, April 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Opiant Pharmaceuticals in a research report on Wednesday, March 16th.
Shares of OPNT opened at $12.47 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 10.10 and a current ratio of 8.72. The stock has a market capitalization of $63.35 million, a P/E ratio of -8.60 and a beta of 0.65. The company’s fifty day moving average is $21.16 and its two-hundred day moving average is $25.91. Opiant Pharmaceuticals has a 1 year low of $7.34 and a 1 year high of $37.71.
Several institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in shares of Opiant Pharmaceuticals by 10.7% in the 1st quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company’s stock worth $160,000 after buying an additional 723 shares in the last quarter. Essex Investment Management Co. LLC boosted its position in shares of Opiant Pharmaceuticals by 2.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 32,040 shares of the technology company’s stock worth $686,000 after buying an additional 777 shares in the last quarter. Morgan Stanley boosted its position in shares of Opiant Pharmaceuticals by 11.8% in the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock worth $101,000 after buying an additional 1,000 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Opiant Pharmaceuticals by 4.0% in the 1st quarter. Parkman Healthcare Partners LLC now owns 32,557 shares of the technology company’s stock valued at $697,000 after purchasing an additional 1,266 shares in the last quarter. Finally, Advisor Group Holdings Inc. lifted its holdings in Opiant Pharmaceuticals by 28.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,125 shares of the technology company’s stock valued at $273,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 27.93% of the company’s stock.
Opiant Pharmaceuticals Company Profile (Get Rating)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Receive News & Ratings for Opiant Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.